{"DataElement":{"publicId":"3536187","version":"1","preferredName":"CA-125 Antigen Based Clinical Study Patient Response Occurrence Date","preferredDefinition":"Calendar date of a CA125-based patient response to protocol treatment.","longName":"CA125_STDY_RESP_DT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3536183","version":"1","preferredName":"CA-125 Antigen Based Clinical Study Patient Response Occurrence","preferredDefinition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumour marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders._Basis; the fundamental assumptions underlying an explanation or a relation that provides the foundation for something._An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._An instance of something happening, such as an event or incident.","longName":"CA125_PT_RESP_OCC","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3536093","version":"1","preferredName":"CA-125 Antigen Basis Clinical Study Protocol","preferredDefinition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumour marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders.:Basis; the fundamental assumptions underlying an explanation or a relation that provides the foundation for something.:An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"C325:C25430:C25320","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CA-125 Antigen","conceptCode":"C325","definition":"An antigen expressed by tissues derived from mullerian epithelium (tubal, endometrial and endocervical) or celomic epithelium (mesothelial cells of the pleura, pericardium and peritoneum).  Although its biochemical nature has not been clearly defined, CA125 has been described as a glycosylated, high-molecular-weight protein that may be released from damaged cells.  Measurable in plasma, CA125 is a sensitive, nonspecific tumor marker for ovarian cancer; as such it is much more useful for monitoring clinical responses to the treatment of ovarian cancer than for the diagnosis of ovarian cancer.  Elevated plasma CA125 may occur in association with other malignancies and non-malignant gynecologic disorders. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Basis","conceptCode":"C25430","definition":"The fundamental assumptions underlying an explanation or a relation that provide the foundation for something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5BF8340-C3AD-E78D-E040-BB89AD435649","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3536181","version":"1","preferredName":"Patient Response Occurrence","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:Occurrence; an instance of something happening.","longName":"C16960:C50995:C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0D4AE-17F4-2CC8-E040-BB89AD433375","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"ONEDATA","dateModified":"2012-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5C0D4AE-1805-2CC8-E040-BB89AD433375","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017121","version":"1","preferredName":"CTMS Date","preferredDefinition":"Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).","longName":"CTMS_DT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":"4","maxLength":"8","minValue":null,"maxValue":null,"decimalPlace":null,"format":"DD/MON/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008561","version":"1","preferredName":"Occurrences","preferredDefinition":"dates, times, and durations.","longName":"OCURS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B53BD1AB-090B-398B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-01-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"A6545B3B-0FC3-40BF-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-07-21","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-21","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/30/17 jk Transferred context, added CSI and reg status, released per Round 5 finalization task. --- Display and exchange formats are based on CTMS reporting requirements v.3.02 and all subsequent versions of these guidelines.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"Date of CA125 Response","type":"Preferred Question Text","description":"Date of CA125 Response","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"C5C0AE69-DBAF-4321-E040-BB89AD4335EE","latestVersionIndicator":"Yes","beginDate":"2012-07-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-26","modifiedBy":"REEVESD","dateModified":"2015-05-19","changeDescription":"Curated to support Duke University clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}